Irish-US specialty pharmaceutical company Shorla Oncology has raised $35m (€33m) in funding from investors including private backers in Ireland and Enterprise Ireland.
CAMBRIDGE, Mass., October 04, 2023 Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, today announced that it has raised $35 million in Series B funding, led by Kurma Partners’ Growth Opportunities Fund, with participation from existing investors Seroba Life Sciences and Irish, U.S. and Canadian based family offices and Enterprise Ireland. The funding will enable Shorla to accelerate the growth of its oncology portfolio by advancing its pipeline, bringing therapies to